Price movement over the last 24 hours
ADMA Biologics Inc vs Dow Jones Industrial Average ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Dow Jones Industrial Average ETF trades at $522.56. The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DIA | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $530.02 |
52-Week Low | $7.60 | $435.72 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $530.02, up 0.41% with a bullish technical signal from moving averages. The ETF tracks the Dow Jones Industrial Average, which recently surpassed 53,000 for the first time, driven by financials and tech exposure. Recent dividend distributions and strong institutional interest support the positive momentum, though oscillators indicate some overbought conditions with RSI levels above 70.
Outlook remains favorable given the Dow's 8% YTD gain and historical 13.3% average annual returns. Key risks include election-year volatility and potential Fed policy shifts under new Chair Kevin Warsh. Investors benefit from blue-chip diversification, but should monitor technical resistance near $533 and broader market sentiment for sustained upside.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →